Home

Federal Government Relations

The 340B Drug Discount Program

Congress created the 340B program in 1992 to help uninsured indigent patients gain better access to prescription medicines. This white paper examines the history and original intent of the program as well as highlights key findings to help policymakers ensure that the 340B program meets its stated purpose and to provide a roadmap for next steps to be considered.

BIO's 2013 Legislative Priorities

Brent Del Monte, BIO’s Vice President of Federal Government Relations, discusses the 113th Congress and BIO’s 2013 legislative priorities.

Biofuels Power the Great Green Fleet

LtGen John "Glad" Castellaw explains how the U.S. military will validate the use of biofuels in military exercises. Terrabon CEO Gary Luce discusses the benefits to commercial aviation of large-scale biofuel production.

Therapeutic Discovery Project Defending America's Competitiveness in Biotechnology

Capital formation challenges in the industry have forced many biotech companies to halt projects, lay off staff or shutdown all together. Our analysis shows that the industry is approximately one-quarter smaller than it was in 2008.

Therapeutic Discovery Project Helps Scientists Working To Cure Cancer

BIO believes that the level of support provided by the TDP simply cannot meet the needs of the growing biotech field. As evidence of the project's popularity suggests, Congress should consider extending or expanding the project in order to support American innovation and speed the development of life-saving cures.

Therapeutic Discovery Project Is Working to Create & Protect American Jobs

The biotech industry is a thriving sector employing 1.3 million Americans in high quality, high paying jobs.

Developing Policies that Foster Innovation

Acorda Therapeutics' Ron Cohen presented testimony on the importance of federal policies to support the biotechnology industry at a House Committee on Science, Space and Technology, Subcommittee on Technology and Innovation hearing on March 27, a summary of his testimony is presented here

The JOBS Act: Critical Support for Today’s Emerging Biotech Company

The House and Senate passed H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. It is now headed to the White House for President Obama’s signature.

OncoMed Pharmaceuticals SVP/CFO on Emerging Company Capital Formation Testimony

William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals, highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth. Mr. Waddill provided testimony today on behalf of BIO at a Senate Committee on Banking, Housing, and Urban Affairs hearing.

BIO Media Briefing Highlights 2012 Policy Priorities

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

Podcast: BIO Media Briefing Highlights 2012 Policy Priorities

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

BIO's 2012 Legislative Priorities - Part II

BIOtech-NOW's Tracy Cooley discusses the legislative year ahead with Brent Del Monte, BIO's Vice President of Federal Government Relations.

2011: A Pivotal Year for Biotechnology

Biotechnology continues to hold the greatest promise to address many of the most critical issues facing our world.

BIO's 2012 Legislative Priorities

BIOtech-NOW's Tracy Cooley discusses the legislative year ahead with Brent Del Monte, BIO's Vice President of Federal Government Relations. In this two part series, Del Monte discusses the outlook for 2012 and legislative priorities.

Therapeutic Discovery Project: 7 Companies, 1 Year Later

The Therapeutic Discovery Project provided much-needed relief for emerging biotech companies  working on life-saving treatments and cures

Letters, Testimony & Comments

Pandemic and All-Hazards Preparedness Reauthorization Act
December 18 2012
Dear Speaker Boehner and Minority Leader Pelosi: On behalf of the Biotechnology Industry Organization (BIO), I am writing with our...
The Renewable Fuels Standard: A Successful Federal Policy that Must Be Defended
October 17 2012
A keynote Address by James C. Greenwood, President & CEO of BIO, to RETECH 2012 in Washington, DC on October 18, 2012. When Admiral...
IP Attache Program: BIO's Congressional Hearing Comments
June 27 2012
  The U.S. Intellectual Property Rights Attaché Program has had significant success and holds immense promise in helping to...
Oppose Costly & Confusing Labeling Amendment to the Agriculture Reform, Food and Jobs Act of 2012
June 21 2012
Senators Sanders and Boxer have introduced an amendment that will result in costly and extreme food labeling requirements. Senate...
The Farm Bill: BIO Opposes the Sanders-Boxer Amendment
June 21 2012
The Biotechnology Industry Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state...
More Letters, Testimony & Comments →

Press Releases

BIO Praises U.S. Senate for Passing the Pandemic and All-Hazards Preparedness Reauthorization Act
February 28 2013
WASHINGTON, DC – February 28, 2013 –The Biotechnology Industry Organization (BIO) lauds the Senate for...
BIO Praises Introduction of the High Technology Small Business Research Incentives Act
September 25 2012
Washington, D.C. (September 25, 2012) – The Biotechnology Industry Organization (BIO) applauds Sens. Robert...
BIO Submits Comments on FDA Draft Guidances on Biosimilars
April 17 2012
Washington, D.C. (April 17, 2012) – The Biotechnology Industry Organization (BIO) submitted comments yesterday...
BIO Applauds Congress for Passage of the Jumpstart Our Business Startups (JOBS) Act
March 27 2012
The Biotechnology Industry Organization (BIO) praises the House and Senate for passage of H.R. 3606, the Jumpstart...
Biotech Leader Provides Testimony at Congressional Hearing on ‘Spurring Job Growth through Capital Formation While Protecting Investors’
March 6 2012
Today, the Senate Committee on Banking, Housing, and Urban Affairs held a hearing on “Spurring Job Growth...
More Press Releases →